IPD
vs
S
S&P/ASX 300
IPD
Over the past 12 months, IPD has underperformed S&P/ASX 300, delivering a return of -88% compared to S&P/ASX 300's +2% growth.
Stocks Performance
IPD vs S&P/ASX 300
Performance Gap
IPD vs S&P/ASX 300
Performance By Year
IPD vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
ImpediMed Ltd
Glance View
ImpediMed Ltd is a medical technology company that makes devices and software for measuring body fluid and tissue composition with bioimpedance spectroscopy. Its best-known product is the SOZO system, which gives clinicians a quick, non-invasive read on fluid changes in patients. The company focuses on turning those measurements into practical tools for early detection and ongoing monitoring, especially in cancer care and heart failure care. The main customers are hospitals, oncology centers, cardiology practices, and other clinics that monitor patients at risk of fluid-related complications such as lymphedema. ImpediMed sells its systems to healthcare providers and also earns recurring income from software, data, and usage-based services tied to the platform. In simple terms, it makes money by placing its measurement tools into clinical workflows and then charging for the hardware and the ongoing access around it. What makes ImpediMed different is that it sits at the point where imaging, monitoring, and digital records meet. Instead of being a general medical equipment maker, it focuses on one specific measurement method that can help clinicians spot changes earlier than a physical exam alone. That gives it a niche role in care pathways where repeated, standardized measurements matter more than one-time testing.
